CGC-11047 HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 200750

CAS#: 206991-64-2 (HCl)

Description: CGC-11047 is a second generation polyamine analogue, synthesized through the restriction of molecular conformations of parent polyamine compounds, with potential antineoplastic activity. Polyamine analogue PG11047 may displace endogenous polyamines from DNA binding sites, thereby interfering with cell cycle processes dependent upon polyamine binding and function, and resulting in cell-cycle arrest, induction of apoptosis, depletion of polyamines, and interference with gene and ligand-receptor activities involved with cell growth. This agent may exhibit decreased toxicity and enhanced cytotoxicity profiles compared to first-generation polyamine compounds. In tumor cells, there is an increase dependence on polyamines as well as a dysregulated polyamine metabolic pathway resulting in abnormal or sustained tumor growth.

Chemical Structure

CGC-11047 HCl
CAS# 206991-64-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 200750
Name: CGC-11047 HCl
CAS#: 206991-64-2 (HCl)
Chemical Formula: C14H36Cl4N4
Exact Mass: 256.2627
Molecular Weight: 402.27444
Elemental Analysis: C, 41.80; H, 9.02; Cl, 35.25; N, 13.93

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 308145-19-9 (free base)   206991-64-2 (HCl)    

Synonym: CGC 11047; CGC-11047; CGC11047; CGC-11047 hydrochloride ; SL 11047; SL11047; SL-11047; SL 47; PG11047; PG-11047.

IUPAC/Chemical Name: (Z)-N1,N1'-(but-2-ene-1,4-diyl)bis(N3-ethylpropane-1,3-diamine) tetrahydrochloride


InChi Code: InChI=1S/C14H32N4.4ClH/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2;;;;/h5-6,15-18H,3-4,7-14H2,1-2H3;4*1H/b6-5-;;;;


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 402.27444 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Dredge K, Kink JA, Johnson RM, Bytheway I, Marton LJ. The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer. Cancer Chemother Pharmacol. 2009 Dec;65(1):191-5. doi: 10.1007/s00280-009-1105-7. Epub 2009 Aug 15. PubMed PMID: 19685053.

2: Hacker A, Marton LJ, Sobolewski M, Casero RA Jr. In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells. Cancer Chemother Pharmacol. 2008 Dec;63(1):45-53. doi: 10.1007/s00280-008-0706-x. Epub 2008 Feb 27. PubMed PMID: 18301893.

3: Mitchell JL, Thane TK, Sequeira JM, Marton LJ, Thokala R. Antizyme and antizyme inhibitor activities influence cellular responses to polyamine analogs. Amino Acids. 2007 Aug;33(2):291-7. Epub 2007 Apr 6. PubMed PMID: 17410332.

4: Lima e Silva R, Kachi S, Akiyama H, Shen J, Hatara MC, Aslam S, Gong YY, Khu NH, Lauer TW, Hackett SF, Marton LJ, Campochiaro PA. Trans-scleral delivery of polyamine analogs for ocular neovascularization. Exp Eye Res. 2006 Nov;83(5):1260-7. Epub 2006 Sep 6. PubMed PMID: 16950258.

5: Loussouarn G, Marton LJ, Nichols CG. Molecular basis of inward rectification: structural features of the blocker defined by extended polyamine analogs. Mol Pharmacol. 2005 Aug;68(2):298-304. Epub 2005 May 4. PubMed PMID: 15872118.

Additional Information